Pathologic Considerations and Standardization in Mesothelioma Clinical Trials

被引：10

作者：

Tsao, Ming-Sound ^{[1
,2
]}

Carbone, Michele ^{[3
]}

Galateau-Salle, Francoise ^{[4
]}

Moreira, Andre L. ^{[5
]}

Nicholson, Andrew G. ^{[6
,7
]}

Roden, Anja C. ^{[8
]}

Adjei, Alex A. ^{[9
]}

Aubry, Marie-Christine ^{[8
]}

Fennell, Dean A. ^{[10
]}

Gomez, Daniel ^{[11
]}

Harpole, David ^{[12
]}

Hesdorffer, Mary ^{[13
]}

Hirsch, Fred R. ^{[14
]}

Liu, Geoffrey ^{[15
]}

Malik, Shakun ^{[16
]}

Nowak, Anna ^{[17
]}

Peikert, Tobias ^{[18
]}

Salgia, Ravi ^{[19
]}

Szlosarek, Peter ^{[20
]}

Taioli, Emanuela ^{[21
,22
]}

Yang, Haining ^{[3
]}

Tsao, Anne ^{[23
]}

Mansfield, Aaron S. ^{[9
]}

机构：

[1] Princess Margaret Canc Ctr, Dept Pathol, Toronto, ON, Canada

[2] Univ Toronto, Toronto, ON, Canada

[3] Univ Hawaii, Canc Ctr, Thorac Oncol Program, Honolulu, HI 96822 USA

[4] Ctr Leon Berard, Dept BioPathol, MESOBANK, MESOPATH,MESONAT, Lyon, France

[5] New York Univ Langone Hlth, Dept Pathol, New York, NY USA

[6] Imperial Coll, Royal Brompton & Harefield NHS Fdn Trust, Dept Histopathol, London, England

[7] Imperial Coll, Natl Heart & Lung Inst, London, England

[8] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA

[9] Mayo Clin, Div Med Oncol, 200 First St SW, Rochester, MN 55905 USA

[10] Leicester Canc Res Ctr, Mesothelioma Res Programme, Leicester, Leics, England

[11] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA

[12] Duke Univ, Dept Surg, Div Cardiothorac Surg, Durham, NC USA

[13] Mesothelioma Appl Res Fdn, Alexandria, VA USA

[14] Tisch Canc Ctr, Ctr Thorac Oncol, Mt Sinai Hlth Syst, New York, NY USA

[15] Princess Margaret Canc Ctr, Toronto, ON, Canada

[16] NCI, Clin Invest Branch, Canc Therapy Evaluat Program, NIH, Bethesda, MD 20892 USA

[17] Univ Western Australia, Natl Ctr Asbestos Related Dis, Nedlands, WA, Australia

[18] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN USA

[19] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA

[20] Queen Mary Univ London, Barts Canc Inst, London, England

[21] Icahn Sch Med Mt Sinai, Dept Epidemiol, New York, NY 10029 USA

[22] Icahn Sch Med Mt Sinai, Dept Thorac Surg, New York, NY 10029 USA

[23] Univ Texas MD Anderson Canc Ctr, Dept Thoracic Head & Neck Med Oncol, Houston, TX 77030 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期

关键词：

Mesothelioma; Clinical trials; Pathology; Correlatives; Pathologic classification; MALIGNANT PLEURAL MESOTHELIOMA; HEALTH-ORGANIZATION CLASSIFICATION; LIGAND; EXPRESSION; REPORTING RECOMMENDATIONS; BRCA1-ASSOCIATED PROTEIN-1; QUALITY-ASSURANCE; NEEDLE-BIOPSY; OPEN-LABEL; T-CELLS; LUNG;

D O I：

10.1016/j.jtho.2019.06.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The accurate diagnosis of mesothelioma is critical for the appropriate clinical management of this cancer. Many issues complicate making the diagnosis of mesothelioma including the presence of reactive mesothelial cells in benign pleural effusions, the heterogeneity of mesothelioma histopathology, the relatively high incidence of other epithelial malignancies that metastasize to the pleura, and primary sarcomas that arise within the pleura. Given the rapidly evolving field of molecular profiling and the need for translational correlates in mesothelioma clinical trials, the National Cancer Institute (NCI)-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting was convened in March 2017 to develop a consensus on standard pathology guidelines for future NCI-sponsored clinical trials in mesothelioma. This consensus statement covers recommendations for specimen handling, pathologic classification and diagnosis, biobanking, and tissue correlative studies. (C) 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

引用

页码：1704 / 1717

页数：14

共 50 条

[1] Commentary: Surgical standardization in mesothelioma trials
Rusch, Valerie W.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2022, 163 (06) : 1949 - 1950
[2] Malignant mesothelioma in situ: diagnostic and clinical considerations
Pulford, Emily
Henderson, Douglas W.
Klebe, Sonja
PATHOLOGY, 2020, 52 (06) : 635 - 642
[3] Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
Gray, Steven G.
Mutti, Luciano
TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 : S100 - S119
[4] Novel immunotherapy clinical trials in malignant pleural mesothelioma
Tano, Zachary E.
Chintala, Navin K.
Li, Xiaoyu
Adusumilli, Prasad S.
ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (11)
[5] Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma
Berardi, Rossana
Fiordoliva, Ilaria
De Lisa, Mariagrazia
Ballatore, Zelmira
Caramanti, Miriam
Morgese, Francesca
Savini, Agnese
Rinaldi, Silvia
Torniai, Mariangela
Tiberi, Michela
Ferrini, Consuelo
Onofri, Azzurra
Cascinu, Stefano
TUMORI JOURNAL, 2016, 102 (02): : 190 - 195
[6] Radiomics in clinical trials: perspectives on standardization
Nie, Ke
Xiao, Ying
PHYSICS IN MEDICINE AND BIOLOGY, 2023, 68 (01)
[7] PRO IO in Mesothelioma Should Only Be Given on Clinical Trials
Bradbury, P.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S235 - S236
[8] Update on the pathologic diagnosis of malignant mesothelioma
Schulte, Jefree J.
Husain, Aliya N.
TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (03) : 917 - 923
[9] Clinical trials in malignant pleural mesothelioma in Australasia
Nowak, AK
LUNG CANCER, 2005, 49 : S113 - S116
[10] Review on clinical trials of targeted treatments in malignant mesothelioma
Jan Nyrop Jakobsen
Jens Benn Sørensen
Cancer Chemotherapy and Pharmacology, 2011, 68 : 1 - 15

← 1 2 3 4 5 →